Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 430 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company’s clinical-stage programs include Antibody Transport Vehicle (ATV): triggering receptors expressed on myeloid cells 2 (TREM2), Protein Transport Vehicle (PTV): progranulin (PGRN), eukaryotic initiation factor 2 B (eIF2B), receptor-interacting serine/threonine protein kinase 1 (RIPK1), Enzyme Transport Vehicle (ETV): iduronate 2-sulfatase (IDS) and leucine-rich repeat kinase 2 (LRRK2), which are in various Phases ranging from Phase I through Phase III. The Company’s product candidates include DNL310, TAK-594/DNL593, TAK-920/DNL919, BIIB122/DNL151, DNL343, SAR443820/DNL788 and SAR443122/DNL758. The firm engineers its product candidates to cross the BBB, and act directly in the brain.